These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 14709725)

  • 1. One less thing to worry about: the shrinking spectrum of tumors in BRCA founder mutation carriers.
    Garber JE; Syngal S
    J Natl Cancer Inst; 2004 Jan; 96(1):2-3. PubMed ID: 14709725
    [No Abstract]   [Full Text] [Related]  

  • 2. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
    Niell BL; Rennert G; Bonner JD; Almog R; Tomsho LP; Gruber SB
    J Natl Cancer Inst; 2004 Jan; 96(1):15-21. PubMed ID: 14709734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.
    Neuhausen SL; Ozcelik H; Southey MC; John EM; Godwin AK; Chung W; Iriondo-Perez J; Miron A; Santella RM; Whittemore A; Andrulis IL; Buys SS; Daly MB; Hopper JL; Seminara D; Senie RT; Terry MB;
    Breast Cancer Res Treat; 2009 Jul; 116(2):379-86. PubMed ID: 18704680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.
    Kauff ND; Perez-Segura P; Robson ME; Scheuer L; Siegel B; Schluger A; Rapaport B; Frank TS; Nafa K; Ellis NA; Parmigiani G; Offit K
    J Med Genet; 2002 Aug; 39(8):611-4. PubMed ID: 12161607
    [No Abstract]   [Full Text] [Related]  

  • 5. Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.
    Smith M; Fawcett S; Sigalas E; Bell R; Devery S; Andrieska N; Winship I
    Fam Cancer; 2008; 7(2):119-24. PubMed ID: 17636421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
    Kirchhoff T; Satagopan JM; Kauff ND; Huang H; Kolachana P; Palmer C; Rapaport H; Nafa K; Ellis NA; Offit K
    J Natl Cancer Inst; 2004 Jan; 96(1):68-70. PubMed ID: 14709740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA germline mutations in women with uterine serous carcinoma--still a debate.
    Lavie O; Ben-Arie A; Segev Y; Faro J; Barak F; Haya N; Auslender R; Gemer O
    Int J Gynecol Cancer; 2010 Dec; 20(9):1531-4. PubMed ID: 21119368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
    Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
    J Natl Cancer Inst; 1999 Dec; 91(24):2112-7. PubMed ID: 10601383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer risks for BRCA1/2 carriers.
    Wacholder S; Struewing JP; Hartge P; Greene MH; Tucker MA
    Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622558
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
    Friedenson B
    J Natl Cancer Inst; 2004 Aug; 96(15):1184-5; author reply 1185-6. PubMed ID: 15292392
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
    Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
    Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer risks for BRCA1/2 carriers.
    Easton DF; Hopper JL; Thomas DC; Antoniou A; Pharoah PD; Whittemore AS; Haile RW
    Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622557
    [No Abstract]   [Full Text] [Related]  

  • 13. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
    J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
    Antoniou AC; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
    J Med Genet; 2005 Jul; 42(7):602-3. PubMed ID: 15994883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
    Bell DW; Erban J; Sgroi DC; Haber DA
    Cancer Res; 2002 May; 62(10):2741-3. PubMed ID: 12019146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.